Indeed, the FDA has recently approved pembrolizumab for the treatment of ESCC patients progressing in 1 or more lines of treatment with a high expression PD-L1 (CPS ≥ 10) (33), based predominantly on the results from KEYNOTE-181. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.